2016 Top markets report
December 23, 2016Medical Communications market, market access
2016 Top Markets Report
Top Ten most popular articles on Pharmafile.com this year
December 23, 2016Medical Communications biggest news, biggest stories, top 10, top 10 stories, top stories, top ten
As we’re now in the New Year, here at Pharmafocus, we thought we would do a recap of the ten …
Merrimack’s breast cancer trial stutters to halt
December 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merrimack Pharmaceuticals, merrimack
Merrimack Pharmaceuticals announced that it had decided to stop a Phase 2 study of MM-302, a HER2 antibody-targeted liposomal doxorubicin, …
Impax Laboratories parts with CEO
December 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Impax Laboratories
Impax Laboratories announced on 20 December that CEO Frederik Wilkinson has left his position of president and CEO, as well …
Seven pharma trends for 2017
December 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing M&A, MA, biosimilars, collaborations, digital pharma, emerging markets, patient centricity, pharma, pricing
What will be the key industry trends in 2017?Industry uncertaintyPerhaps the biggest hallmark of 2016-going-into-2017 is the sense of hesitation …
Fluor wins $2 billion Novo contract to build API manufacturing facility
December 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Fluor, Novo Nordisk, north carolina
Fluor Corporation has won an engineering, procurement and construction management contract for Novo Nordisk’s $2 billion diabetes active pharmaceutical ingredient …
Actelion acquisition hokey-cokey continues with J&J returning to table
December 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, Johnson & Johnson, Sanofi
The Actelion takeover saga continues with Johnson & Johnson back in the game, and now re-entering into exclusive negotiations. Actelion …
Sun Pharma to acquire Novartis’s drug for $175 million
December 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, Sun Pharma
Sun Pharma has announced that it will acquire Odomzo from Novartis for an upfront fee of $175 million alongside additional …
Roche’s ground-breaking MS drug delayed by manufacturing issues
December 22, 2016Genentech, MS, Roche, multiple sclerosis
Roche has released both good and bad news just before Christmas. The good news is very good news for individuals …
Colombian government forces through near half-price cut of Novartis drug
December 21, 2016Medical Communications, Sales and Marketing Colombia, Novartis
The Colombian government has lowered the price of Glivec (imatinib) by 44%, a cancer drug made by Novartis. The case …
New research reverses HIV-related immune suppression
December 21, 2016Research and Development HIV, UNC School of Medicine
The UNC School of Medicine has released new research which appears to offer a new approach to HIV treatment which …
FDA new drug approvals sink to six year low
December 21, 2016Medical Communications, Research and Development FDA, NDA, new drug approvals
The FDA has released figures to show that drug approvals have fallen from last year’s high of 45 new drugs …
Allergan shells out $2.9bn for regenerative medicine unit LifeCell
December 21, 2016Research and Development, Sales and Marketing Allergan, LifeCell, acquisition
Allergan has agreed a deal to acquire Acelity-owned regenerative medicine unit LifeCell for $2.9 billion in cash, assimilating its portfolio …
Novartis seals two deals to bolster drug pipeline
December 21, 2016Research and Development Conatus, Encore Vision, Novartis
Novartis has consolidated its ophthalmology position by acquiring Encore Vision, a Fort Worth-based US company. The company is focused on …
AZ oncology head leaves to become Innate Pharma chairman
December 21, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Innate Pharma
French firm Innate Pharma has announced that the current-AstraZeneca head of oncology is joining the company as chairman of the …
Treatment using light and deep-sea bacteria kills cancer cells
December 20, 2016Medical Communications, Research and Development Vascular-targeted photodynamic therapy
A technique called vascular-targeted photodynamic therapy (VTP) has been developed that sent 49% of patients suffering from prostate cancer into …
Japan announces measure to crack down on drug pricing
December 20, 2016Manufacturing and Production, Medical Communications Japan, Shinzo Abe, opdivo
Japan has committed to annual drug price reviews whilst also expanding the scope by which the prices are deemed to …
J&J’s largest India site to finally operate by 2018
December 20, 2016Manufacturing and Production India, Johnson & Johnson
Johnson & Johnson has reportedly announced that its manufacturing plant in Telangana, India, its largest site in the country, is …
AstraZeneca opens £120 million UK manufacturing facility
December 20, 2016Manufacturing and Production AstraZeneca, Macclesfield
AstraZeneca has officially opened a new manufacturing facility for cancer medicines based in Macclesfield, UK. It becomes the second largest …
AZ oncology head leaves to become Innate Pharma chairman
December 19, 2016Manufacturing and Production, Sales and Marketing AstraZeneca, Innate Pharma
French firm Innate Pharma has announced that the current-AstraZeneca head of oncology is joining the company as chairman of the …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
